BAKER BROS. ADVISORS LP
13F Reported Value
ⓘ$17.4B
Holdings
84
Latest Filing
2026-03-31
Filing Quarter
Q1 2026
Portfolio Overview
BAKER BROS. ADVISORS LP disclosed 84 positions worth $17.4B in its Form 13F-HR for Q1 2026, led by $INCY (INCYTE CORP) at 16.6% of the equity portfolio, followed by $ONC and $INSM. During the quarter the fund opened 7 new positions and exited 9 — including a new stake in $MIRM and a full exit from $RARE. The portfolio is most concentrated in Healthcare (100.0% of disclosed assets). All figures are sourced directly from BAKER BROS. ADVISORS LP’s Form 13F-HR filing with the SEC under CIK 1263508.
AI Fund Analysis
StableSector Allocation
AUM History
Top Equity Holdings by Value
Quarterly Activity — Q1 2026
Click any card to unlockTop Holdings
- 81.2#34
Quality
$2.9B30,744,412 sh - —
Quality
$2.6B8,799,053 sh - 29.4#2,409
Quality
$1.2B7,421,111 sh - 25.4
Quality
$1.1B2,141,701 sh - 69.8
Quality
$954.9M42,896,690 sh - —
Quality
$929.3M9,555,357 sh - —
Quality
$903.5M7,915,792 sh - —
Quality
$759.3M19,919,186 sh - 29.2
Quality
$721.1M8,657,242 sh - —
Quality
$690.0M36,391,063 sh
| Company | Quality | Value | Shares |
|---|---|---|---|
 INCYTE CORP$INCY | 81.2#34 | $2.9B | 30,744,412 |
 BeOne Medicines Ltd.$ONC | — | $2.6B | 8,799,053 |
 INSMED Inc$INSM | 29.4#2,409 | $1.2B | 7,421,111 |
 MADRIGAL PHARMACEUTICALS, INC.$MDGL | 25.4 | $1.1B | 2,141,701 |
 ACADIA PHARMACEUTICALS INC$ACAD | 69.8 | $954.9M | 42,896,690 |
 Revolution Medicines, Inc.$RVMD | — | $929.3M | 9,555,357 |
 Celcuity Inc.$CELC | — | $903.5M | 7,915,792 |
 Kodiak Sciences Inc.$KOD | — | $759.3M | 19,919,186 |
 Kymera Therapeutics, Inc.$KYMR | 29.2 | $721.1M | 8,657,242 |
 Summit Therapeutics Inc.$SMMT | — | $690.0M | 36,391,063 |
Unlock AI quality scores for every holding
32-signal composite ranking on each of BAKER BROS. ADVISORS LP's 84 positions.
Showing top 10 of 84 holdings.
Sector Allocation
Healthcare
$17.4B
Full Holdings — BAKER BROS. ADVISORS LP (Q1 2026)
All 84 disclosed positions from the latest Form 13F-HR, with quarter-over-quarter share changes and 13F Pro quality scores. Sourced from SEC EDGAR.
| # | Ticker | Company | Value | Weight | QoQ | Quality |
|---|---|---|---|---|---|---|
| 1 | $INCY | INCYTE CORP | $2.9B | 16.6% | +0% | 81.2 |
| 2 | $ONC | BeOne Medicines Ltd. | $2.6B | 15.0% | +0% | — |
| 3 | $INSM | INSMED Inc | $1.2B | 7.0% | +13% | 29.4 |
| 4 | $MDGL | MADRIGAL PHARMACEUTICALS, INC. | $1.1B | 6.4% | +0% | 25.4 |
| 5 | $ACAD | ACADIA PHARMACEUTICALS INC | $954.9M | 5.5% | +0% | 69.8 |
| 6 | $RVMD | Revolution Medicines, Inc. | $929.3M | 5.3% | +1% | — |
| 7 | $CELC | Celcuity Inc. | $903.5M | 5.2% | +0% | — |
| 8 | $KOD | Kodiak Sciences Inc. | $759.3M | 4.4% | +0% | — |
| 9 | $KYMR | Kymera Therapeutics, Inc. | $721.1M | 4.1% | +0% | 29.2 |
| 10 | $SMMT | Summit Therapeutics Inc. | $690.0M | 4.0% | +0% | — |
| 11 |  $PRAX | Praxis Precision Medicines, Inc. | $564.9M | 3.2% | +56% | — |
| 12 |  $RYTM | RHYTHM PHARMACEUTICALS, INC. | $487.4M | 2.8% | +0% | 30.3 |
| 13 |  $ALKS | Alkermes plc. | $354.0M | 2.0% | +0% | — |
| 14 |  $GRAL | GRAIL, Inc. | $208.2M | 1.2% | +93% | 31.9 |
| 15 |  $EWTX | Edgewise Therapeutics, Inc. | $207.1M | 1.2% | +0% | — |
| 16 |  $IONS | IONIS PHARMACEUTICALS INC | $153.8M | 0.9% | +14% | 37.1 |
| 17 |  $KNSA | Kiniksa Pharmaceuticals International, plc | $136.1M | 0.8% | +0% | — |
| 18 |  $IMVT | Immunovant, Inc. | $135.6M | 0.8% | +0% | — |
| 19 |  $ROIV | Roivant Sciences Ltd. | $134.8M | 0.8% | -12% | — |
| 20 |  $IDYA | IDEAYA Biosciences, Inc. | $131.5M | 0.8% | +9% | 10.5 |
| 21 |  $ARWR | ARROWHEAD PHARMACEUTICALS, INC. | $124.9M | 0.7% | -8% | 74.4 |
| 22 |  $STOK | Stoke Therapeutics, Inc. | $108.6M | 0.6% | +0% | 53.4 |
| 23 |  $IMTX | Immatics N.V. | $107.4M | 0.6% | -10% | — |
| 24 |  $ABCL | AbCellera Biologics Inc. | $105.7M | 0.6% | +10% | 17.2 |
| 25 |  $ABVX | Abivax S.A. | $97.5M | 0.6% | +0% | — |
| 26 |  $CRNX | Crinetics Pharmaceuticals, Inc. | $85.4M | 0.5% | +43% | 26.5 |
| 27 |  $REPL | Replimune Group, Inc. | $84.5M | 0.5% | +0% | — |
| 28 | $CELC | Celcuity Inc. | $74.9M | 0.4% | +0% | — |
| 29 |  $NRIX | Nurix Therapeutics, Inc. | $72.2M | 0.4% | +0% | 13.2 |
| 30 |  $DNLI | Denali Therapeutics Inc. | $71.6M | 0.4% | +0% | — |
| 31 |  $DNTH | Dianthus Therapeutics, Inc. /DE/ | $71.5M | 0.4% | +8% | 26.8 |
| 32 |  $GLUE | Monte Rosa Therapeutics, Inc. | $71.5M | 0.4% | +0% | 18.1 |
| 33 |  $GPCR | Structure Therapeutics Inc. | $69.0M | 0.4% | +0% | — |
| 34 |  $TRDA | Entrada Therapeutics, Inc. | $64.0M | 0.4% | +0% | 8.5 |
| 35 |  $BCYC | BICYCLE THERAPEUTICS PLC | $50.5M | 0.3% | +0% | — |
| 36 |  $SYRE | Spyre Therapeutics, Inc. | $50.4M | 0.3% | +0% | — |
| 37 |  $RAPP | Rapport Therapeutics, Inc. | $48.4M | 0.3% | +0% | — |
| 38 |  $ALMS | ALUMIS INC. | $44.3M | 0.3% | +29% | 9.2 |
| 39 |  $MIRM | Mirum Pharmaceuticals, Inc. | $41.2M | 0.2% | NEW | 32.7 |
| 40 |  $VRDN | Viridian Therapeutics, Inc.\DE | $38.6M | 0.2% | +0% | 30.5 |
| 41 |  $ELVN | Enliven Therapeutics, Inc. | $35.5M | 0.2% | +234% | — |
| 42 |  $PRLD | Prelude Therapeutics Inc | $34.6M | 0.2% | +0% | 27 |
| 43 |  $DBVT | DBV Technologies S.A. | $30.5M | 0.2% | +0% | 6.1 |
| 44 |  $DSGN | Design Therapeutics, Inc. | $27.5M | 0.2% | +16% | — |
| 45 |  $CNTA | Centessa Pharmaceuticals plc | $26.6M | 0.1% | +0% | — |
| 46 |  $CTMX | CytomX Therapeutics, Inc. | $23.4M | 0.1% | +17% | 19.1 |
| 47 |  $JBIO | Jade Biosciences, Inc. | $23.1M | 0.1% | +0% | — |
| 48 |  $IRON | Disc Medicine, Inc. | $22.4M | 0.1% | +4% | — |
| 49 |  $IMCR | Immunocore Holdings plc | $22.1M | 0.1% | -68% | — |
| 50 |  $XENE | Xenon Pharmaceuticals Inc. | $21.5M | 0.1% | +0% | 12.9 |
| 51 |  $CLDX | Celldex Therapeutics, Inc. | $21.1M | 0.1% | +0% | 13.2 |
| 52 |  $NGNE | Neurogene Inc. | $20.0M | 0.1% | +0% | — |
| 53 |  $EVMN | Evommune, Inc. | $19.5M | 0.1% | NEW | — |
| 54 |  $TECX | Tectonic Therapeutic, Inc. | $18.8M | 0.1% | -33% | — |
| 55 |  $CTNM | Contineum Therapeutics, Inc. | $18.6M | 0.1% | +0% | — |
| 56 |  $ARGX | ARGENX SE | $18.4M | 0.1% | +0% | — |
| 57 |  $CERS | CERUS CORP | $18.2M | 0.1% | +0% | 29.3 |
| 58 |  $TSHA | Taysha Gene Therapies, Inc. | $17.9M | 0.1% | +0% | 4.1 |
| 59 |  $AKTS | Aktis Oncology, Inc. | $17.8M | 0.1% | NEW | — |
| 60 |  $GENB | Generate Biomedicines, Inc. | $17.8M | 0.1% | NEW | — |
| 61 |  $SION | Sionna Therapeutics, Inc. | $16.0M | 0.1% | +0% | — |
| 62 |  $DYN | Dyne Therapeutics, Inc. | $14.7M | 0.1% | +0% | — |
| 63 |  $XNCR | Xencor Inc | $13.3M | 0.1% | +0% | 13.1 |
| 64 |  $CMPS | COMPASS Pathways plc | $13.0M | 0.1% | NEW | — |
| 65 |  $RLAY | Relay Therapeutics, Inc. | $11.5M | 0.1% | +0% | 12.7 |
| 66 |  $SERA | SERA PROGNOSTICS, INC. | $11.2M | 0.1% | +0% | 7.9 |
| 67 |  $BNTX | BioNTech SE | $10.6M | 0.1% | -68% | — |
| 68 |  $PHVS | Pharvaris N.V. | $10.6M | 0.1% | +0% | — |
| 69 |  $RCUS | Arcus Biosciences, Inc. | $9.0M | 0.1% | +54% | 12 |
| 70 |  $MPLT | MapLight Therapeutics, Inc. | $7.4M | 0.0% | +0% | — |
| 71 |  $ABSI | Absci Corp | $6.4M | 0.0% | +0% | 4.4 |
| 72 |  $WVE | Wave Life Sciences Ltd. | $6.0M | 0.0% | +139% | — |
| 73 |  $VTVT | vTv Therapeutics Inc. | $5.9M | 0.0% | +0% | — |
| 74 |  $EIKN | Eikon Therapeutics, Inc. | $5.9M | 0.0% | NEW | — |
| 75 |  $TARA | Protara Therapeutics, Inc. | $5.1M | 0.0% | +0% | — |
| 76 |  $SGMT | Sagimet Biosciences Inc. | $5.0M | 0.0% | +0% | — |
| 77 |  $LBRX | LB PHARMACEUTICALS INC | $4.9M | 0.0% | +0% | — |
| 78 |  $VSTM | Verastem, Inc. | $3.1M | 0.0% | NEW | 40.8 |
| 79 |  $TCRX | TScan Therapeutics, Inc. | $2.8M | 0.0% | +0% | 8.7 |
| 80 |  $SKYE | Skye Bioscience, Inc. | $968,144 | 0.0% | +9% | — |
| 81 |  $SANA | Sana Biotechnology, Inc. | $894,191 | 0.0% | +0% | — |
| 82 |  $ALGS | Aligos Therapeutics, Inc. | $617,099 | 0.0% | +0% | — |
| 83 |  $TYRA | Tyra Biosciences, Inc. | $406,248 | 0.0% | +0% | — |
| 84 |  $SRZN | Surrozen, Inc./DE | $13,333 | 0.0% | +0% | — |
New Positions (7)
Browse Top Institutional Investors
13F Pro tracks 8,700+ institutional investors filing 13F reports with the SEC.
to search all 8,700+ institutional filers.
Available Analysis
13F Pro tracks comprehensive institutional data for BAKER BROS. ADVISORS LP including:
Track BAKER BROS. ADVISORS LP's Full Portfolio
See every holding, quarter-over-quarter changes, sector allocation, and accumulation patterns for BAKER BROS. ADVISORS LP and 8,700+ other institutional investors.
Free tier includes full 13F search and fund profiles. Pro starts at $6.67/mo (billed annually).
AI-Powered Hedge Fund Analysis: BAKER BROS. ADVISORS LP
13F Pro is an AI hedge fund tracker and stock research platform. For BAKER BROS. ADVISORS LP (SEC CIK: 1263508), the platform ingests every quarterly Form 13F filing and applies AI-powered analysis on top — 10 specialized AI analysts (value, growth, momentum, macro, activist, and more) debate the fund's top positions and publish AI-generated analysis with cited SEC sources.
Every holding in BAKER BROS. ADVISORS LP's portfolio is scored on a 32-signal AI quality ranking (ROIC, FCF margin, revenue growth, institutional flow, earnings quality, shareholder dilution, and more). Track accumulation and distribution quarter over quarter, identify conviction positions, and see AI stock analysis for each position — alongside 8,700+ other institutional filers and 2,800+ AI-ranked companies.